Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

VJVirtual | AML: the cytogenetic risk score

Arnon Nagler • 31 Mar 2020
Acute Myeloid Leukemia Leukemia

Arnon Nagler, MD, MSc, Sheba Medical Center, Tel-Aviv, Israel, discusses the cytogenetic abnormalities seen in acute myeloid leukemia (AML), the development of a cytogenetic risk score and how this is important to allogeneic stem cell transplantation (ASCT). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Arnon Nagler

Evaluating the impact of donor age on alloSCT outcomes in patients with secondary AML in CR1 2:01
Evaluating the impact of donor age on alloSCT outcomes in patients with secondary AML in CR1
Arnon Nagler • 6 Dec 2025
Transplanting patients with advanced AML 3:07
Transplanting patients with advanced AML
Arnon Nagler • 30 Mar 2025
Bone marrow versus mobilized peripheral blood grafts for haploidentical transplant in secondary AML 1:42
Bone marrow versus mobilized peripheral blood grafts for haploidentical transplant in secondary AML
Arnon Nagler • 30 Mar 2025
Is there a preferable donor for alloSCT in secondary AML in first complete remission? 2:23
Is there a preferable donor for alloSCT in secondary AML in first complete remission?
Arnon Nagler • 30 Mar 2025

Related Videos

BGB-16673 in patients with R/R CLL/SLL: updated results from the ongoing Phase I CaDAnCe-101 study 1:41
BGB-16673 in patients with R/R CLL/SLL: updated results from the ongoing Phase I CaDAnCe-101 study
Inhye Ahn • 6 Dec 2025
Measures of financial toxicity during pediatric ALL treatment: report from the DFCI ALL 16-001 trial 5:45
Measures of financial toxicity during pediatric ALL treatment: report from the DFCI ALL 16-001 trial
Daniel Zheng • 7 Dec 2025
Press briefing: results from the ACCESS trial 10:36
Press briefing: results from the ACCESS trial
Antonio Jimenez-Jimenez • 7 Dec 2025
BRUIN CLL-314 study: pirtobrutinib versus ibrutinib in treatment-naïve and R/R CLL/SLL 6:46
BRUIN CLL-314 study: pirtobrutinib versus ibrutinib in treatment-naïve and R/R CLL/SLL
Jennifer Woyach • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals